Clincosm LogoSign in Get a demo

AMLREGISTRY: Acute Myeloid Leukemia Registry

Sponsor
Turkish Hematology Association (Other)
Overall Status
Recruiting
CT.gov ID
NCT05979675
Collaborator
(none)
250
Enrollment
1
Location
60
Anticipated Duration (Months)
4.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.

    Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.

    All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    250 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study
    Actual Study Start Date :
    Dec 21, 2021
    Anticipated Primary Completion Date :
    Dec 21, 2026
    Anticipated Study Completion Date :
    Dec 21, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Overall Survival [60 months]

      From diagnosis to exits by any cause

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Diagnosed as AML after 1 Jan 2020

    • Patients signed informed consent form

    Exclusion Criteria:
    • Patients under 18 years old

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Antalya Training and Research Hospital Antalya Turkey

    Sponsors and Collaborators

    • Turkish Hematology Association

    Investigators

    • Study Director: Ilker Kurkcu, Sentez Cro

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Turkish Hematology Association
    ClinicalTrials.gov Identifier:
    NCT05979675
    Other Study ID Numbers:
    • AML_Registry
    First Posted:
    Aug 7, 2023
    Last Update Posted:
    Aug 7, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Leukemia
    Leukemia, Myeloid
    Leukemia, Myeloid, Acute

    Study Results

    No Results Posted as of Aug 7, 2023